February 15, 2022
RegMed Investors’ (RMi) closing bell: a beautiful day in the sector’s neighborhood
February 14, 2022
RegMed Investors’ (RMi) closing bell: interpreting the cell and gene therapy sector’s decline
February 11, 2022
RegMed Investors’ (RMi) closing bell: the week ends with an empty bottle of cell and gene therapy advancements
February 10, 2022
RegMed Investors’ (RMi) closing bell: cell and gene sector gets shot down and crashes in flames
February 9, 2022
RegMed Investors’ (RMi) closing bell: riding the sector merry-go-round
February 8, 2022
RegMed Investors’ (RMi) closing bell: we had a pitcher in this session, the pitcher's nick-name - Algorithm
February 7, 2022
RegMed Investors’ (RMi) closing bell: another bounce, dips got bought yet, the sector could end-up with overbought and volatile bottoms again
February 4, 2022
RegMed Investors’ (RMi) closing bell: Volatility fell, volume was lower in a positive cell and gene therapy sector close
February 3, 2022
RegMed Investors’ (RMi) closing bell: another wild run
February 2, 2022
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector got hammered as predicted, when is it wrong to be so right and often?
February 1, 2022
RegMed Investors’ (RMi) closing bell: are you making a return on investments (ROI) or waiting for the down slide
January 31, 2022
RegMed Investors’ (RMi) closing bell: I said, take the highs and sell them, there’s always a question of how long the upsides will last
January 28, 2022
RegMed Investors’ (RMi) closing bell: a daily reversal with a big positive sector close after a frustrating week for cell and gene therapy investors
January 27, 2022
RegMed Investors’ (RMi) closing bell: the costs of the roller-coaster sector rides
January 26, 2022
RegMed Investors’ (RMi) closing bell: I loved the smell of appreciation in the morning until the algorithms napalmed the cell and gene therapy sector
January 25, 2022
RegMed Investors’ (RMi) closing bell: wild volatility charges the slips and slides as the sector’s come-back collapses
January 24, 2022
RegMed Investors’ (RMi) closing bell: panic sector selling and then a major comeback
January 21, 2022
RegMed Investors’ (RMi) closing bell: sector trades accelerate risk aversion tumbles
January 20, 2022
RegMed Investors’ (RMi) closing bell: finally, the oversold were appreciative until the lower reverse unfolded
January 19, 2022
RegMed Investors’ (RMi) closing bell: a tightening cycle
January 18, 2022
RegMed Investors’ (RMi) closing bell: wipe-out
January 14, 2022
RegMed Investors’ (RMi) closing bell: a late session rebound, a bouncing sector rotates to close positive
January 13, 2022
RegMed Investors’ (RMi) closing bell: sector is still shackled by selling
January 12, 2022
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector went off the road and into a ditch, again
January 11, 2022
RegMed Investors’ (RMi) closing bell: sector volatility works to our favor in this market
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.